Skip to content
Screener

Exelixis EXEL Shares (Diluted)

Shares (Diluted) at other companies

Eli Lilly logo
Eli LillyLLY
893.7M-0.7%
Pfizer logo
PfizerPFE
5.7B-0.1%
Kura Oncology logo
Kura OncologyKURA
88.6M+1.4%
Immunome logo
ImmunomeIMNM
113.1M+42.5%
Arcus Biosciences logo
Arcus BiosciencesRCUS
126.1M+18.4%
Opko Health logo
Opko HealthOPK
755.3M-4.2%

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$14.25B+40.4%
Enterprise value$14.14B+39.0%
P/E16.6×-0.3×
P/S5.9×+1.3×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Provision for income taxes50,62845,567107,84891,641
Net income$212,050$184,848$422,517$344,464
Net income per share:
Basic$0.85$0.68$1.66$1.25
Diluted$0.82$0.65$1.60$1.20
Weighted-average common shares outstanding:
Basic250,808272,583254,568275,693
Diluted259,675284,393263,499286,285

Item 1. Financial Statements.

FAQ

What is Exelixis's shares (diluted)?
Exelixis (EXEL) reported shares (diluted) of 259.7M in Q2 2026.
How has Exelixis's shares (diluted) changed year-over-year?
Exelixis's shares (diluted) decreased by 8.7% year-over-year, from 284.4M to 259.7M.
What is the long-term trend for Exelixis's shares (diluted)?
Over 4 years (2021 to 2025), Exelixis's shares (diluted) has grown at a -3.2% compound annual growth rate (CAGR), from 1.3B to 1.1B.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Exelixis's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude